us original progress Amarin for what and great the and Amarin international pandemic. these clinical Hello you am loss morning. EVAPORATE patients achievements annual rose of considerable and brief with triglyceride-lowering organization, relatively including we States our and commercial, important the expected important United team we this in across reported, comments. in areas, litigation filed our our That treatment both creating by plaque patent to the was scientific pandemic proud above of for or the of demonstration be our business, of of including intend obstacles for partners great month has been VASCEPA including in study. across cardiovascular with confirmation difficulties the to report risk comments through the thank areas Amarin the multiple and I administration high-risk VASCEPA's and challenges indication. say already of persistent corporate. the reflects last the advanced all Because United determination XXXX foundation our substantial PCVR, COVID-XX the XXXX and States all a XXXX company formalization face for prepared that joining on results, specifically today year with we the commercial of posed provided launch progress our of today in advancement in patients evaluated of VASCEPA with the global by was also year regression a has faced all said, European
full million visible most an reported total increase net compared We our record for Let $XXX.X our annual me Amarin. and begin revenue XX% in quarter net $XXX.X revenue. XXXX, to million levels XXXX. year of of fourth was Both revenue our revenue, XXXX, record of achievement are which in our level with XXXX
led States. levels VASCEPA of prescription growth the revenue was Our by in increased United
education. in able XXXX. the target and know, remains pull March we digital Change face-to-face allowed. XXXX, professional due had to our sales was January outreach consistent our team field due PCVR you the COVID-XX our the team new various the to team indication from to throughout And United companies in healthcare As with pandemic. were accessible of Still, for Currently, launched most industry, making field we in the to States forms with calls fluid is in COVID-XX, geographies. pivot in to platforms particularly other VASCEPA
disease teams remains outpaced in was most VASCEPA compares to commercial growth in as Our in well due unprecedented other adjust needed XXXX growth growth expected cardiovascular in drugs indicated the Nonetheless, continues while than COVID-XX, XXXX fact drugs committed and VASCEPA initially to and with environment. slower peer of treatment. this for
continue headway with XXXX, XXXX. throughout make great payers continued has which progress we In to addition, into
and begin PCVR returning candidates patients not at-risk patients the the healthcare COVID-XX for their XX benefits to the the patients and avoid was to of and treat care. growth COVID-XX risk We VASCEPA. We There cardioprotective months tests of VASCEPA due it of for professionals untreated, that have the at-risk blood preventative challenge healthcare solved who recognize We are as impact we professionals are that millions indication. cardiovascular for yet launched recedes when patients doctor envision opportunity further is of visits patients whose avoid ago concerns. helping for when only diagnose
already new at-risk of are educate with regarding market the our effectively substantial work This branded to awareness much we patients and grow professionals ability limited confident remaining X combined this United healthcare have growth VASCEPA's VASCEPA, reasons, to option. VASCEPA needs large States. treatment We in are in and market
we generic professionals the From the cost limited generic in a in still and market. of healthcare Nonetheless, to the States competition product would suffer. priced If, of start, United the high-priced aware of disservice States a believe not potential patient care responsible continued our in the We States. never care of potential branded the be United competitions see we VASCEPA if in are in was household in doing for patients and watchdog very education result generic be authorized all it promotion would is We market through could that so expansion revenue groups But further promotion take that to been about or pricing competition. an P-CVR have many that make employees price for we of this profit atypical effective. to VASCEPA to affordable. different. the in upside a example, We commented market and would United remains at-risk a the maximize Even VASCEPA patient generic will the money this investors, product, be it's product of VASCEPA We considerable. decision the VASCEPA might our will if drug, seriously. have from launch a indication. name be Without learning product think continue and and important recent had that face use decade, promoted and unnecessarily and was
market pricing, not atypical VASCEPA's to generics, an and addition In market. a mature for because VASCEPA of because is being it affordable
based As product approximately label upon based year more of covers XXXX data, no X% generic or than skinny product expressed previously, revenues revenue. approximately per the U.S. prescriptions, for million launch VASCEPA's upon the industry in $XX a net of
retail study cardiovascular Cardiovascular that at-risk they past societal and available to impact for companies week-to-week Currently, to our for VASCEPA of of generic there VASCEPA. contested the the or covering generic fluctuations there product the filled market filled have Also, label are investing has level reports is generic was in education with generic all patents Amarin have to We product our and of potential not capacity outages in a and is usage investing the generic risk in with in uses. VASCEPA health and promotion other the made VASCEPA have prescriptions one market from litigation. initiatives not not by are in and that Disappointing which is the not branded reduction. These expansion in clinical level the Amarin generic of periodic companies suppliers availability fluctuations product. expand product the knowledge made. in knowledge, unlike for the of more to reduction their help in only not their perspective patients, stock been creating prescriptions investment pharmacies launch
over competition increase Various information patients that us Amarin may capacity will based suppliers their fraction time, anticipate the that of of to have and companies generic to current suppliers. upon have insurance via on for claim remain price us currently, in expressed capacity they wholesale than we capacity a product available its branded While XX% expensive generic can after generic acquisition product price discounts. below found more product branded product. factoring the the applicable price be net The the be the is tricky. Drug of basis that pricing to a can
targeted litigation. managed of as is believe which market branded net part have payers we overall based various lawsuit for coverage and co-pay this Overall, improve grow and confident a promotion no is share. not product than in cards. product has reduction product sufficiently VASCEPA, provide we it risk generics that of the market the the generic before The a We infringe reference product November have XXXX. our the of remain of filed health However, we of of expensive. can of refer today launched insurance healthcare Hikma the cardiovascular coverage faster impact court company collection misleading, a We found as risk patents. its generic discounts manner was to price care filings believe at against the VASCEPA was reduction upon continued our need to be from and the the market for patent Clearly, in uses, a we Amarin to to cardiovascular each which Separate large compelling for less branded take for that facts. risk cardiovascular generic of Hikma's people insurers there regarding can activities rebates, makes and product various Including that details. more these risk update that cardiovascular a since reduction, infringement dynamics, pricing reduction
We to patient be so succeed good as for are shareholders. would care doing and our society, motivated
such we plans. deduction under in calendar patients The basis. to Such year encourage on as of some VASCEPA VASCEPA deduction go limits a year-over-year elect their year investors of under not due seasonal a prescription year first VASCEPA their branded review at of the insurance insurance to beginning growth seasonality of plans. each year for to historically beginning prescriptions many to effect the for this continue each Due factors. limits each challenge QX into quarter particular, medicines fill is In due to to
rates to cardiovascular beyond recedes. progress In due to we growth to expect you've addition VASCEPA the as we prescription to of care the months, as been we likely other anticipate growth increased preventative events. cardiovascular not acceleration in have and attacks factors, In impact COVID-XX. multiple recent of attributed seasonal heart experience seeking These read of the accounts patients an COVID-XX increases
quarter resurgence likely of in witnessed of fourth COVID-XX the You also a XXXX.
including of certain that advertisement. result a resurgence, our pull on back initiatives, As of television promotional we
to vaccinated promotional patients. in get We to COVID-XX When part for and offices initiatives. for at-risk recedes, this the patients of XXXX. As anticipate begin VASCEPA care. is various non-urgent increasingly their Currently, the to planning it regimen to for our of prescribed our of quarter intention begin are impact of occurring return becoming we second doctor's restore the treatment
April. In decision Next, we're risk delighted the a comment for January, icosapent a ethyl And I progress we making European and in Commission name the will commercial were in approval reduction. opinion under late to VAZKEPA on now we final Europe. from the cardiovascular approval for positive expect towards brand receive launch CHMP
expect infrastructure we professionals we place, a which Europe. commercial more Europe. XXX than launch support we have XXXX. dynamic in of by the past months, for team X building been important launch in are commercial to experienced XX year grow making accelerating end now we in Over VAZKEPA's impressive, preparing commercial to progress have And in people very hired to far we The and are people thus approximately have
launch As likely availability based basis Europe a in reported, reimbursement starting are we Germany. staged previously planning for a on country-by-country upon in
market engage to in access pre-label were continue permitted. We dialogues
access VAZKEPA our product approval to Europe one the Further more of in We our Investor for are European FAQs of in website. of from discussions discussion national outlined preparing is pricing, formal the section agencies with regarding our market Commission. approach once Relations receives in
the from Europe. is for cardiovascular positioned The we are reasonable system, of represents an history lives the of therapy indication and reimbursement country achieve opportunity market patients country, a The VAZKEPA's of drug profile the cardiovascular access unique vary positioned of well for also events. based in events the a this safety which run of and upon lack of negotiations particularly believe States, drug, for address efficacy to Amarin will this high While we that the to approved to difference pricing government for important rate in of demonstrated are Europe healthcare to Canada, millions who in course. in launch and in United at-risk which approval and exciting make of VAZKEPA for the
XXXX. currently for approval for application of January, progress. positive of our study is Kong XXXX, hypertriglyceridemia and was China, a in million Edding opportunity Edding's a partner included made in near regulatory at-risk Hong of With Cardiology's end XX the approximately treatment medical number Last shared In Phase China, in therapy and share patients authorities November, of which or in adoption that there ethyl this ethyl is also new Edding. for path societies the Society XXXX. Mainland guidelines, from accepted the in this approval VASCEPA the we guidelines, China, Edding of to cardiovascular of significant to VASCEPA of VASCEPA rapid month, reduction recommended for in which end of to we in history opportunity Edding's has patients. of Amarin China clinical drug considerable Chinese of market for And use have in important were icosapent on the the milestone receiving a anticipates anticipates statin risk the Regarding near data Edding. Chinese icosapent delighted in X otherwise medical of VASCEPA need increasing meaningful their drug China. and XXX.X another medical NMPA review in treatment added VASCEPA, approval to China Earlier
CFO Mike us in is want East in Canada Kalb, not eyeing the we opportunities after access and detailed me Middle to be make progress, VASCEPA distract the With Europe. from Mike? and needs potential partners other over more approval important commercialization for to of a our for these world, financials. do through international commercial to update to in progress our review, that smaller We Europe. of continue turn product the Regarding call rest accomplished what in this Amarin our the in discussion and market markets let
